Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Long-term Extension Study to Evaluate Safety and Efficacy of Atumelnant in Participants With Congenital Adrenal Hyperplasia (CALM2-CAH)

NCT06712823 is registered in ClinicalTrials.gov with Crinetics Pharmaceuticals Inc. as lead sponsor.

NCT NCT06712823
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06712823 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Long-term Extension Study to Evaluate Safety and Efficacy of Atumelnant in Participants With Congenital Adrenal Hyperplasia (CALM2-CAH)
Lead sponsor
Crinetics Pharmaceuticals Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
February 25, 2025
Completion date
August 31, 2029
Enrollment
200 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

classic congenital adrenal hyperplasia, congenital adrenal hyperplasia